Morningstar

Pfizer Licenses Weight-Loss Drug Candidate From Fosun Unit

Provided by Dow Jones

By Colin Kellaher 




  Pfizer is licensing a potential weight-loss drug from a unit of Shanghai Fosun Pharmaceutical in a collaboration potentially worth more than $2 billion for the Chinese healthcare company. 



  Pfizer on Tuesday said the agreement covers the development, manufacturing and commercialization of YP05002, a GLP-1 receptor agonist currently in Phase 1 development for chronic weight management. 



  GLP-1 drugs mimics a gut hormone to help suppress appetite. 



  Pfizer said it will make an upfront payment of $150 million to Fosun's YaoPharma unit for an exclusive worldwide license to YP05002. 



  The New York drugmaker said YaoPharma will also be eligible to receive up to $1.935 billion in development, regulatory and commercial milestone payments, along with royalties on sales. 



  Pfizer said the addition of YP05002 complements and strengthens its portfolio of candidates for treating obesity and its adjacent diseases, adding that it plans to study the drug with its PF-07976016 candidate that is currently in Phase 2 development, along with other small molecules in its pipeline. 





  Write to Colin Kellaher at colin.kellaher@wsj.com 





  (END) Dow Jones Newswires



  December 09, 2025 07:37 ET (12:37 GMT)


Copyright (c) 2025 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
 
Ask the Analyst columnist Amy Arnott answers a grab bag of reader questions about bond ETFs, TIPS, retirement planning, and more. 
 
 
Amy C. Arnott, CFA and Ivanna Hampton 
 
 
 
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
 
With a 3.3% dividend yield and earnings growth expected to exceed management’s outlook, this 4-star stock stands out in a struggling sector. 
 
 
Andrew Bischof, CFA, CPA 
 
 
 
The Thrilling 37
 
Just a few strict screens can narrow the field to an elite group of funds. 
 
 
Russel Kinnel 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for October
 
Plus, lessons from September’s stock market activity. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
The 10 Best and 10 Worst Months of All Time for the US Stock Market
 
Do common investor sayings about particular months being stronger or weaker for stocks have empirical backing, or is it all market mythology? Dan Lefkovitz uncovered some surprising truths about stock market performance by examining over 100 years of data. 
 
 
Dan Lefkovitz 
 
 
 
 

			Sponsor Center